O Dzahini1,2, N Singh3, D Taylor1,2, P M Haddad3,4. 1. 1 Institute of Pharmaceutical Science, King's College London, London, UK. 2. 2 South London and Maudsley NHS Foundation Trust, London, UK. 3. 3 Department of Psychiatry, Hamad Medical Corporation, Doha, Qatar. 4. 4 University of Manchester, Manchester, UK.
Abstract
OBJECTIVES: The purpose of this study was to investigate the association of antipsychotic exposure to the incidence and mortality of pneumonia. METHODS: The design of this study involved meta-analysis of observational studies identified from electronic databases. RESULTS: In total, 19 studies were included in the systematic review and 14 in the meta-analysis. Risk of pneumonia was increased by first-generation antipsychotics (risk ratio 1.69, 95% confidence interval 1.34-2.15; five studies), second-generation antipsychotics (risk ratio 1.93, 95% confidence interval 1.55-2.41; six studies) and all antipsychotics (risk ratio 1.83, 95% confidence interval 1.60-2.10; seven studies) compared with no antipsychotic use. Pneumonia risk did not differ in seven studies comparing first-generation antipsychotics with second-generation antipsychotics (risk ratio 1.07, 95% confidence interval 0.85-1.35). Case fatality rate was not different in pneumonia cases associated with antipsychotic exposure versus cases without exposure (risk ratio 1.50; 95% confidence interval 0.76-2.96; two studies). All antipsychotics with data from ⩾2 studies allowing meta-analysis, were associated with a significantly increased pneumonia risk (i.e. haloperidol, olanzapine, clozapine, risperidone, quetiapine, zotepine). CONCLUSION: Exposure to both first-generation antipsychotics and second-generation antipsychotics is associated with an increased pneumonia risk. Clinicians need to be vigilant for the occurrence of pneumonia in patients commencing antipsychotics, especially those with other risk factors for pneumonia including older age, chronic respiratory disease, cerebrovascular disease, dysphagia and smoking.
OBJECTIVES: The purpose of this study was to investigate the association of antipsychotic exposure to the incidence and mortality of pneumonia. METHODS: The design of this study involved meta-analysis of observational studies identified from electronic databases. RESULTS: In total, 19 studies were included in the systematic review and 14 in the meta-analysis. Risk of pneumonia was increased by first-generation antipsychotics (risk ratio 1.69, 95% confidence interval 1.34-2.15; five studies), second-generation antipsychotics (risk ratio 1.93, 95% confidence interval 1.55-2.41; six studies) and all antipsychotics (risk ratio 1.83, 95% confidence interval 1.60-2.10; seven studies) compared with no antipsychotic use. Pneumonia risk did not differ in seven studies comparing first-generation antipsychotics with second-generation antipsychotics (risk ratio 1.07, 95% confidence interval 0.85-1.35). Case fatality rate was not different in pneumonia cases associated with antipsychotic exposure versus cases without exposure (risk ratio 1.50; 95% confidence interval 0.76-2.96; two studies). All antipsychotics with data from ⩾2 studies allowing meta-analysis, were associated with a significantly increased pneumonia risk (i.e. haloperidol, olanzapine, clozapine, risperidone, quetiapine, zotepine). CONCLUSION: Exposure to both first-generation antipsychotics and second-generation antipsychotics is associated with an increased pneumonia risk. Clinicians need to be vigilant for the occurrence of pneumonia in patients commencing antipsychotics, especially those with other risk factors for pneumonia including older age, chronic respiratory disease, cerebrovascular disease, dysphagia and smoking.
Authors: Paula D Strassle; Emily E Sickbert-Bennett; Michael Klompas; Jennifer L Lund; Paul W Stewart; Ashley H Marx; Lauren M DiBiase; David J Weber Journal: Infect Control Hosp Epidemiol Date: 2019-10-29 Impact factor: 3.254
Authors: H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen Journal: Encephale Date: 2020-05-04 Impact factor: 1.291
Authors: Giovanni Ostuzzi; Davide Papola; Chiara Gastaldon; Georgios Schoretsanitis; Federico Bertolini; Francesco Amaddeo; Alessandro Cuomo; Robin Emsley; Andrea Fagiolini; Giuseppe Imperadore; Taishiro Kishimoto; Giulia Michencigh; Michela Nosé; Marianna Purgato; Serdar Dursun; Brendon Stubbs; David Taylor; Graham Thornicroft; Philip B Ward; Christoph Hiemke; Christoph U Correll; Corrado Barbui Journal: BMC Med Date: 2020-07-15 Impact factor: 8.775
Authors: Martin Maripuu; Marie Bendix; Louise Öhlund; Micael Widerström; Ursula Werneke Journal: Front Psychiatry Date: 2021-01-08 Impact factor: 4.157
Authors: Felicia Ceban; Danica Nogo; Isidro P Carvalho; Yena Lee; Flora Nasri; Jiaqi Xiong; Leanna M W Lui; Mehala Subramaniapillai; Hartej Gill; Rene N Liu; Prianca Joseph; Kayla M Teopiz; Bing Cao; Rodrigo B Mansur; Kangguang Lin; Joshua D Rosenblat; Roger C Ho; Roger S McIntyre Journal: JAMA Psychiatry Date: 2021-10-01 Impact factor: 25.911